Say announces Synairgen’s exciting breakthrough in severe flu treatment

Say is to publicise an exciting UK breakthrough from respiratory drug discovery and development company Synairgen.  Synairgen has developed a new flu drug that ‘switches on’ the lungs’ natural defences to flu and flu-like viruses, preventing the spread of infection from cell to cell even after infection has taken hold.  The development could have a significant impact on the treatment of both seasonal and pandemic flu, with potentially positive implications for patient outcome and the financial burden on the NHS.  The development was announced at the American Thoracic Society’s International Conference, with Say drafted in to transmit the information to UK print and online media.

For more information go to